Neurological Institute Outcomes
Brain Tumors
Brain Tumor Distributions
The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC) of the Neurological Institute is one of the largest and most comprehensive programs in the country and is dedicated to providing exceptional patient care including surgery, radiation, chemotherapy, and clinical research trials for brain tumor patients. Patient care is provided by a multidisciplinary team consisting of neurosurgeons, radiation oncologists, neuro-oncologists, medical oncologists, psychiatrists, and neuropsychologists, along with nurses, advanced practice providers, case managers, and social workers who all specialize in treating patients with brain tumors. The department is dedicated to bringing novel treatment options emerging from the institute’s extensive basic and translational research programs. The primary mission is to offer excellent care through state-of-the-art surgical intervention and conducting clinical research to enhance patient outcomes. The BBTC enrolled 404 patients in therapeutic research trials in the past 5 years (2018–2022).
Brain Tumor Diagnosis Distribution (N = 1797)
2022
In 2022, gliomas were the most common primary brain tumor seen in The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. Metastases were the most common tumor seen in the center.